A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms

TET2 is frequently mutated in myeloid neoplasms. Genetic TET2 deficiency leads to skewed myeloid differentiation and clonal expansion, but minimal residual TET activity is critical for survival of neoplastic progenitor and stem cells. Consistent with mutual exclusivity of TET2 and neomorphic IDH1/2...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Cancer Discov
Main Authors: Guan, Yihong, Tiwari, Anand D., Phillips, James G., Hasipek, Metis, Grabowski, Dale R., Pagliuca, Simona, Gopal, Priyanka, Kerr, Cassandra M., Adema, Vera, Radivoyevitch, Tomas, Parker, Yvonne, Lindner, Daniel J., Meggendorfer, Manja, Abazeed, Mohamed, Sekeres, Mikkeal A., Mian, Omar Y., Haferlach, Torsten, Maciejewski, Jaroslaw P., Jha, Babal K.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Association for Cancer Research 2020
נושאים:
Research Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935131/
https://ncbi.nlm.nih.gov/pubmed/33681816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2643-3230.BCD-20-0173
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים